Change in disease activity needed for meaningful change in cutaneous lupus by patient characteristic: A retrospective analysis of a longitudinal database
- PMID: 37806526
- DOI: 10.1016/j.jaad.2023.09.077
Change in disease activity needed for meaningful change in cutaneous lupus by patient characteristic: A retrospective analysis of a longitudinal database
Keywords: cutaneous lupus erythematosus; discoid lupus erythematosus; skin of color; subacute cutaneous lupus erythematosus.
Conflict of interest statement
Conflicts of interest Dr Werth has grants from Celgene, Janssen, Pfizer, Biogen, Gilead, Corbus Pharmaceuticals, Genentech, AstraZeneca, Viela, Syntimmune, Amgen, Regeneron, Argenx, CSL Behring, Ventus, q32 Bio, BMS, and Horizon and has consulted for Celgene, Genentech, Janssen, Lilly, Pfizer, Biogen, BMS, Gilead, Amgen, Medscape, Nektar, Incyte, EMD Sorona, CSL Behring, Principia, Crisalis, Viela Bio, Argenx, Kwoya Kirin, Regeneron, Principia, AstraZeneca, AbbVie, Octapharma, GSK, Astra-Zeneca, Cugene, UCB, Corcept, Beacon Bioscience, Rome Pharmaceuticals, Horizon, Gilead, Merck, Kezar, Sanofi, Bayer, Akari, Calyx, and Cabaletta Bio. The University of Pennsylvania owns the copyright for the CLASI. Kleitsch, Author Pandya, Dr Chakka, Dr Yan, Dr Lim, Author Diaz, and Dr Feng have no conflicts of interest to declare.
Comment on
-
Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus.J Am Acad Dermatol. 2021 Jun;84(6):1562-1567. doi: 10.1016/j.jaad.2020.07.047. Epub 2020 Jul 16. J Am Acad Dermatol. 2021. PMID: 32682879 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
